Atyr pharma inc (LIFE)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Mar'14
Cash flows from operating activities:
Consolidated net income (loss)

-15,874

-23,763

-23,952

-25,421

-29,985

-34,515

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-55,173

-

-61,782

-59,292

-54,989

-47,973

0

0

0

0

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization

625

635

657

694

729

746

728

689

671

713

773

843

893

900

905

907

893

869

0

0

0

0

Issuance of common stock for technology

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,411

0

0

0

-

Stock-based compensation

1,635

1,783

1,960

2,372

3,074

3,431

5,964

6,463

6,435

6,784

4,801

4,836

5,026

5,029

6,264

6,090

5,533

4,856

0

0

0

-

Debt discount accretion and non-cash interest expense

635

707

779

852

1,086

966

919

845

634

590

0

0

0

-

-

-

-

-

-

-

-

-

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

223

-

0

0

0

0

Change in fair value of preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-29

0

0

0

0

Accretion of discount of available-for-sale investment securities

202

284

293

342

303

261

312

218

124

-14

-148

-247

-341

-531

-806

-994

-1,049

-789

0

0

0

0

Amortization of right-of-use assets

763

731

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of property and equipment

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-130

-211

-291

-320

-315

-310

-305

-300

-295

0

0

0

0

Changes in operating assets and liabilities
Collaboration receivable

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-473

-334

-437

-51

-747

-610

-141

-253

55

-761

-1,318

109

503

421

411

-1,225

-379

666

0

0

0

0

Accounts payable and accrued expenses

569

162

-78

-1,094

-2,044

-2,058

-4,303

-3,253

-1,096

-2,889

-1,769

-3,495

-4,707

-932

3,338

4,374

4,162

3,944

0

0

0

0

Contract liability

-487

208

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

-11,932

-20,013

-19,936

-22,143

-26,509

-31,063

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-54,258

-

-51,001

-45,781

-43,002

-36,797

0

0

0

0

Purchases of property and equipment

235

79

47

55

106

594

745

1,150

1,548

1,312

1,198

821

548

600

673

991

855

664

0

0

0

0

Purchases of available-for-sale investment securities

29,733

40,647

51,592

47,004

46,306

40,299

35,745

89,558

74,171

77,672

67,147

17,654

29,584

28,089

0

0

0

-

-

-

-

-

Maturities of available-for-sale investment securities

49,600

45,600

55,600

64,565

68,815

78,065

72,265

65,997

55,097

51,347

52,840

49,415

53,666

62,216

0

0

0

-

-

-

-

-

Proceeds from sale of property and equipment

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

19,686

4,925

4,012

17,532

22,403

37,172

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Purchases of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Maturities of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

23,534

-

28,829

29,379

-59,429

-71,994

0

0

0

0

Proceeds from issuance of preferred stock for cash, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

75,648

0

0

0

-

Costs paid in connection with initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Proceeds from issuance of common stock through option exercises

-

-

-

-

-

-

-

-

193

-

37

24

10

20

91

90

546

604

0

0

0

0

Proceeds from issuance of common stock through at the market offerings, net of offering costs

-

4,405

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock through underwritten follow-on offering, net of offering costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayments on borrowings

8,000

8,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

18,734

1,336

1,718

-154

-4,865

-4,238

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayments on loans payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

Repayments on notes payable to bank

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

5,525

-

-3,549

-3,473

102,018

147,917

0

0

0

0

Net change in cash and cash equivalents

-

-

-

-

-

-

-

0

-6,964

-

-4,567

-7,276

-25,199

-14,637

-25,721

-19,875

-413

39,126

0

0

0

0

Supplemental schedule of noncash investing and financing activities:
Deferred initial public offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-